As of close of business last night, LifeStance Health Group Inc’s stock clocked out at $6.01, down -0.66% from its previous closing price of $6.05. On the day, 731745 shares were traded.
Ratios:
To gain a deeper understanding of LFST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.11. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on January 03, 2024, initiated with a Underweight rating and assigned the stock a target price of $7.
On May 15, 2023, TD Cowen Downgraded its rating to Market Perform which previously was Outperform and also upped its target price recommendation from $8 to $9.
Morgan Stanley Upgraded its Equal-Weight to Overweight on January 06, 2023, while the target price for the stock was maintained at $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 15 ’24 when Burdick Kenneth A sold 214,605 shares for $6.28 per share. The transaction valued at 1,347,719 led to the insider holds 2,934,372 shares of the business.
Mullins Kevin Michael sold 44,540 shares of LFST for $281,938 on Mar 14 ’24. The Chief Development Officer now owns 4,745,352 shares after completing the transaction at $6.33 per share. On Mar 14 ’24, another insider, Pardo Ryan, who serves as the insider of the company, sold 39,384 shares for $6.33 each. As a result, the insider received 249,301 and left with 817,777 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LFST now has a Market Capitalization of 2.29B and an Enterprise Value of 2.72B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.17 while its Price-to-Book (P/B) ratio in mrq is 1.59. Its current Enterprise Value per Revenue stands at 2.57 whereas that against EBITDA is -25.90.
Stock Price History:
Over the past 52 weeks, LFST has reached a high of $9.59, while it has fallen to a 52-week low of $4.74. The 50-Day Moving Average of the stock is 6.57, while the 200-Day Moving Average is calculated to be 7.19.
Shares Statistics:
It appears that LFST traded 1.39M shares on average per day over the past three months and 954.91k shares per day over the past ten days. A total of 378.73M shares are outstanding, with a floating share count of 84.31M. Insiders hold about 77.85% of the company’s shares, while institutions hold 23.34% stake in the company. Shares short for LFST as of Mar 15, 2024 were 20.79M with a Short Ratio of 14.97, compared to 26.54M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.46% and a Short% of Float of 26.64%.
Earnings Estimates
As of right now, 5 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.12, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.05 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.23 and -$0.32 for the fiscal current year, implying an average EPS of -$0.28. EPS for the following year is -$0.21, with 6 analysts recommending between -$0.15 and -$0.28.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $298.99M. It ranges from a high estimate of $303.07M to a low estimate of $296.73M. As of the current estimate, LifeStance Health Group Inc’s year-ago sales were $252.59M, an estimated increase of 18.40% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for LFST’s current fiscal year. The highest revenue estimate was $1.24B, while the lowest revenue estimate was $1.21B, resulting in an average revenue estimate of $1.22B. In the same quarter a year ago, actual revenue was $1.06B, up 15.60% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $1.38B in the next fiscal year. The high estimate is $1.43B and the low estimate is $1.33B. The average revenue growth estimate for next year is up 13.20% from the average revenue estimate for this year.
